Literature DB >> 16109610

Primary breast lymphoma: outcome of 7 patients and a review of the literature.

Maria Luigia Vigliotti1, Matteo Dell'olio, Antonio La Sala, Nicola Di Renzo.   

Abstract

Primary breast lymphomas (PBL) are uncommon neoplasms. Seven PBL were diagnosed between March 1993 and October 2002. A lumpectomy (n=4) or radical mastectomy (n=3) was performed; 5 patients were in clinical stage (CS) II and 2 in CS IV; 6 patients received the CEOP regimen (cyclophosphamide, vincristine, epirubicin and prednisone) after surgery and 4 also had additional radiotherapy; 1 patient did not receive any treatment after local excision. Five patients (71%) achieved complete remission and 2 (29%) partial remission, with an overall response rate of 100%. All remitter patients are alive and well after a median follow-up of 75 months (range 10--121 months). Two patients in partial remission died of progressive disease. After a median follow-up of 99 months (range 84--111 months) for surviving patients, the 10 year overall and disease-free survival rates are both 71%, with 5 patients well and still free of disease. We conclude that the optimal sequence of full-dose anthracycline-containing regimens and radiation therapy should be the treatment of choice for patients with PBL.

Entities:  

Mesh:

Year:  2005        PMID: 16109610     DOI: 10.1080/10428190500126083

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Anaplastic large-cell non-Hodgkin's lymphoma of the breast in periprosthetic localisation 32 years after treatment for primary breast cancer--a case report.

Authors:  Florian Rudolf Fritzsche; Stefan Pahl; Iver Petersen; Mick Burkhardt; Anja Dankof; Manfred Dietel; Glen Kristiansen
Journal:  Virchows Arch       Date:  2006-09-16       Impact factor: 4.064

2.  Primary breast lymphoma: A single-centre experience.

Authors:  Mang Yik Foo; Wai Peng Lee; Chin Mui Jaime Seah; Carmen Kam; Su-Ming Tan
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-17

3.  Primary non-Hodgkin's lymphoma of the breast: eight-year follow-up experience.

Authors:  Hai-Yi Guo; Xin-Min Zhao; Jin Li; Xi-Chun Hu
Journal:  Int J Hematol       Date:  2008-04-15       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.